BACKGROUND: The incidence of thyroid cancer is four to five times higher in women than in men, suggesting a role for estrogen (E₂) in the pathogenesis of thyroid proliferative disease (TPD) that comprises cancer and goiter. The objective of this study was to investigate the antiestrogenic activity of 3,3'-diindolylmethane (DIM), a bioactive compound derived from cruciferous vegetables, in patients with TPD. METHODS: In this limited phase I clinical trial study, patients found to have TPD were administered 300 mg of DIM per day for 14 days. Patients subsequently underwent a total or partial thyroidectomy, and tissue, urine, and serum samples were collected. Pre- and post-DIM serum and urine samples were analyzed for DIM levels as well as estrogen metabolites. DIM levels were also determined in thyroid tissue samples. RESULTS: DIM was detectable in thyroid tissue, serum, and urine of patients after 14 days of supplementation. Urine analyses revealed that DIM modulated estrogen metabolism in patients with TPD. There was an increase in the ratio of 2-hydroxyestrones (C-2) to 16α-hydroxyestrone (C-16), consistent with antiestrogenic activity that results in more of C-2 product compared with C-16. CONCLUSION: Our data suggest that DIM enhances estrogen metabolism in TPD patients and can potentially serve as an antiestrogenic dietary supplement to help reduce the risk of developing TPD. The fact that DIM is detected in thyroid tissue implicates that it can manifest its antiestrogenic activity in situ to modulate TPD.
BACKGROUND: The incidence of thyroid cancer is four to five times higher in women than in men, suggesting a role for estrogen (E₂) in the pathogenesis of thyroid proliferative disease (TPD) that comprises cancer and goiter. The objective of this study was to investigate the antiestrogenic activity of 3,3'-diindolylmethane (DIM), a bioactive compound derived from cruciferous vegetables, in patients with TPD. METHODS: In this limited phase I clinical trial study, patients found to have TPD were administered 300 mg of DIM per day for 14 days. Patients subsequently underwent a total or partial thyroidectomy, and tissue, urine, and serum samples were collected. Pre- and post-DIM serum and urine samples were analyzed for DIM levels as well as estrogen metabolites. DIM levels were also determined in thyroid tissue samples. RESULTS:DIM was detectable in thyroid tissue, serum, and urine of patients after 14 days of supplementation. Urine analyses revealed that DIM modulated estrogen metabolism in patients with TPD. There was an increase in the ratio of 2-hydroxyestrones (C-2) to 16α-hydroxyestrone (C-16), consistent with antiestrogenic activity that results in more of C-2 product compared with C-16. CONCLUSION: Our data suggest that DIM enhances estrogen metabolism in TPDpatients and can potentially serve as an antiestrogenic dietary supplement to help reduce the risk of developing TPD. The fact that DIM is detected in thyroid tissue implicates that it can manifest its antiestrogenic activity in situ to modulate TPD.
Authors: Edwin K Chan; Daniel W Sepkovic; Helen J Yoo Bowne; Guo Pei Yu; Stimson P Schantz Journal: Otolaryngol Head Neck Surg Date: 2006-06 Impact factor: 3.497
Authors: A Pasagian-Macaulay; E N Meilahn; H L Bradlow; D W Sepkovic; A M Buhari; L Simkin-Silverman; R R Wing; L H Kuller Journal: Steroids Date: 1996-08 Impact factor: 2.668
Authors: G Ursin; S London; F Z Stanczyk; E Gentzschein; A Paganini-Hill; R K Ross; M C Pike Journal: J Natl Cancer Inst Date: 1999-06-16 Impact factor: 13.506
Authors: Kathie M Dalessandri; Gary L Firestone; Mark D Fitch; H Leon Bradlow; Leonard F Bjeldanes Journal: Nutr Cancer Date: 2004 Impact factor: 2.900
Authors: E N Meilahn; B De Stavola; D S Allen; I Fentiman; H L Bradlow; D W Sepkovic; L H Kuller Journal: Br J Cancer Date: 1998-11 Impact factor: 7.640
Authors: Dina Nikitina; Marcia Llacuachaqui; Daniel Sepkovic; H Leon Bradlow; Steven A Narod; Joanne Kotsopoulos Journal: Fam Cancer Date: 2015-06 Impact factor: 2.375
Authors: Cynthia A Thomson; H H Sherry Chow; Betsy C Wertheim; Denise J Roe; Alison Stopeck; Gertraud Maskarinec; Maria Altbach; Pavani Chalasani; Chuan Huang; Meghan B Strom; Jean-Philippe Galons; Patricia A Thompson Journal: Breast Cancer Res Treat Date: 2017-05-30 Impact factor: 4.872
Authors: Shilpi Rajoria; Robert Suriano; Andrea L George; Ameet Kamat; Stimson P Schantz; Jan Geliebter; Raj K Tiwari Journal: J Transl Med Date: 2012-05-01 Impact factor: 5.531
Authors: J Kotsopoulos; S Zhang; M Akbari; L Salmena; M Llacuachaqui; M Zeligs; P Sun; S A Narod Journal: Br J Cancer Date: 2014-07-15 Impact factor: 7.640